Pre-Surgical Combination Therapy Enhances Survival in Rare Thyroid Cancer Patients
Combining pembrolizumab with targeted therapies significantly improves survival and surgical resection rates in patients with aggressive BRAF-mutated anaplastic thyroid cancer.
A recent study from The University of Texas MD Anderson Cancer Center has demonstrated that a pre-surgical combination treatment involving pembrolizumab, dabrafenib, and trametinib significantly improves outcomes in patients with BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC). This Phase II multicenter trial revealed that adding immunotherapy to targeted therapies not only increased the likelihood of tumor resection, with 74% of patients able to undergo surgery compared to just 5% with previous treatments, but also extended overall survival from an average of 14.5 to 18 months.
Anaplastic thyroid cancer is known for its aggressive nature, often presenting with tumors that are difficult to remove surgically. The study’s lead investigator, Dr. Mark Zafereo, noted that traditional treatments offered limited benefits, typically extending survival by only a few months. In contrast, incorporating pembrolizumab, an immunotherapy agent, alongside dabrafenib and trametinib—which inhibit the mutant BRAF protein—enabled better disease control.
Patients enrolled in the study between September 2021 and January 2025 received a median of four therapy cycles before surgery, with 30 out of 40 patients undergoing tumor removal. The combination therapy also doubled the progression-free survival, from approximately 6.7 months to over a year, indicating a delay in cancer progression.
While side effects such as kidney injury, sepsis, and intestinal tear were observed, the results suggest that this approach could become a new standard of care for BRAFm-ATC, especially for patients with the specific BRAF mutation. The study’s limitations include its small size, lack of a control group, and limited follow-up duration.
This research underscores the potential of combining immunotherapy with targeted treatments to improve surgical outcomes and prolong survival in aggressive thyroid cancers. Further studies are needed to confirm these findings and establish long-term benefits.
Source: https://medicalxpress.com/news/2025-06-pre-surgical-combination-therapy-boosts.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Proteoglycan Family Molecules Offer Promising Advances in Breast Cancer Diagnosis and Treatment
Recent research uncovers the potential of proteoglycan molecules as biomarkers and therapeutic targets in breast cancer, promising advances in diagnosis and personalized treatment strategies.
promising results from clinical trial: low-dose interleukin-2 may extend survival in ALS patients
A recent clinical trial reveals that adding low-dose interleukin-2 to standard ALS treatment can slow disease progression and significantly extend patient survival, offering new hope for this devastating neurodegenerative disorder.
Exposure to Green Spaces Promotes Brain Development in Adolescents
New research finds that exposure to green spaces enhances brain development in adolescents, supporting better academic and mental health outcomes. Discover the neurobiological benefits of natural environments for youth development.
